Committee staff report to the chairman and ranking member
Subtitle: review of the FDA's approval process for the vagus nerve stimulation therapy system for treatment-resistant depression
By: prepared by the staff of the Committee on Finance, United States Senate ; Charles E. Grassley, chairman, Max Baucus, ranking member
Contributors: United States. Congress. Senate. Committee on Finance
Series: S. prt -- 109-45
Publisher: U.S. G.P.O.; For sale by the Supt. of Docs., U.S. G.P.O.
Published: 2006
Place of publication: Washington
Language: eng
Number of pages: 386
Subjects: United States. -- Food and Drug Administration -- Rules and practice; Depression, Mental -- Treatment -- Government policy -- United States; Transcutaneous electrical nerve stimulation -- Therapeutic use -- Government policy -- United States; Vagus nerve
Other titles: Review of the FDA's approval process for the vagus nerve stimulation therapy system for treatment-resistant depression
Notes: At head of title: 109th Congress, 2d session, Committee print

"Printed for the use of the Committee on Finance."

Distributed to some depository libraries in microfiche

Shipping list no.: 2006-0141-P

Includes bibliographical references

Also available via Internet from the Finance Committee web site. Address as of 4/27/06: http://finance.senate.gov/press/Gpress/02%5F2006%20report.pdf; current access available via PURL